Phathom Pharmaceuticals to Present at Three March Investor Conferences
Event summary
- Phathom Pharmaceuticals will present at three investor conferences in March 2026.
- Management to participate in TD Cowen's Health Care Conference on March 2, Jefferies' Biotech Summit on March 10, and Barclays' Global Healthcare Conference on March 11.
- Live webcasts and archived recordings will be available for 90 days post-event.
- Phathom focuses on GI treatments, including vonoprazan (VOQUEZNA) for GERD and H. pylori.
The big picture
Phathom Pharmaceuticals is intensifying its investor outreach amid growing competition in the GI therapeutics space. The company's focus on vonoprazan, a first-in-class PCAB, positions it as a niche player, but its ability to scale commercialization will be critical for long-term success. These conferences provide a platform to highlight its pipeline and market differentiation.
What we're watching
- Market Positioning
- How Phathom's conference presentations will shape investor perception of its GI portfolio.
- Execution Risk
- Whether the company can sustain momentum in commercializing vonoprazan post-conference engagements.
- Strategic Outreach
- The pace at which Phathom secures partnerships or licensing deals following these investor discussions.
Our editorial coverage: